

October 20, 2022

To,
Dy. General Manager
Department of Corporate Services,
India Ltd., BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

To,
The Manager – Listing,
The National Stock Exchange of
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Glenmark becomes the First Company in India to launch Teneligliptin + Dapagliflozin Fixed Dose Combination, for Adults with Type 2 Diabetes, having Comorbidities

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Encl: as above

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Glenmark becomes the First Company in India to launch Teneligliptin + Dapagliflozin Fixed Dose Combination, for Adults with Type 2 Diabetes, having Comorbidities

- *Glenmark is the first company in India to launch Teneligliptin (20 mg) + Dapagliflozin (5 mg/10 mg) fixed dose combination (FDC).*
- *With this new launch, the company aims to improve glycemic control in adult patients with uncontrolled type-2 diabetes, especially the ones with comorbidities.*
- *This anti-diabetic FDC medication will be marketed under brand name Zita D.*

Mumbai, India, October 20, 2022: Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven global pharmaceutical company, became the first to launch *Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed dose combination (FDC)* for the treatment of adult patients with type 2 diabetes, especially the ones with comorbidities. Marketed under the brand name Zita D; it contains Teneligliptin (20mg) + Dapagliflozin (5 mg/10 mg), and must be taken once daily under prescription to improve glycemic control & prevent complications in adult patients with type 2 diabetes, especially the ones with comorbidities.

On the launch, Alok Malik, EVP & Business Head - India Formulations, Glenmark Pharmaceuticals, said, "Diabetes is growing in India at an alarming rate, and eight out of every ten diabetic patients suffer from comorbidities. Glenmark being a leader in the diabetes segment in India is proud to bring Zita D, a well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities."

Teneligliptin is a widely used DPP4i (Dipeptidyl Peptidase 4) inhibitor whereas Dapagliflozin is the most prescribed SGLT-2i (Sodium glucose co-transporter 2) inhibitor for diabetic patients in the country. While Zita D is a promising treatment option in managing uncontrolled Type 2 diabetes with co-morbidities, this FDC has also proven to be effective among adult diabetic patients without comorbidities. Glenmark's Zita D is priced at around INR 14 per tablet for FDC of Teneligliptin 20mg + Dapagliflozin 5mg, and INR 15 per tablet for FDC of Teneligliptin 20 mg + Dapagliflozin 10 mg, per day.

Glenmark's Leadership in the diabetes segment

Glenmark has a strong legacy of bringing new and effective treatment options for diabetic patients. In 2015, Glenmark revolutionized diabetes treatment in India by being the first to launch the DPP4 inhibitor – Teneligliptin, followed by a fixed dose combination of Teneligliptin + Metformin. In continuation towards its legacy, Glenmark launched Remogliflozin, a novel SGLT-2 inhibitor in 2019 after its first global approval in India and subsequently launched its combinations with metformin and Vildagliptin. Earlier in 2022, Glenmark launched Sitagliptin and its FDCs, followed by Lobeglitazone.

Diabetes in India

According to IQVIA™ sales data for the 12-month period ending Sept. 2022, the market for oral anti-diabetic drugs in India is estimated to be INR 11,796 cr. with an annual growth of 7% against the corresponding period last year (MAT Sept. 2021). As per the International Diabetes Federation (IDF), the prevalence of diabetes in India is expected to increase to 125 million by 2045ⁱⁱ Out of these, 77% of patients have uncontrolled diabetesⁱⁱⁱ. Moreover, about eight out of ten patients with diabetes also have one or more comorbidity in India^{iv}.

---End---

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark is ranked among the world's top 100 biopharmaceutical companies (Top 100 Companies Ranked by Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the world's top 50 companies in the off-patent sector (Top 50 Generics and Biosimilars Companies ranked by Sales, 2020, by Generics Bulletin/In Vivo). The company was listed on the Dow Jones Sustainability Index (DJSI), one of the world's most respected and widely accepted sustainability benchmarks, under the category of emerging markets (2021) for the fourth consecutive year. For more information, visit www.glenmarkpharma.com, LinkedIn (Glenmark Pharmaceuticals), Instagram (glenmark_pharma).

For more information, please contact

Udaykumar Murthy | +91 9960377617 | corpcomm@glenmarkpharma.com

References

ⁱ ORG MAT March 2022 – Calculated on annualized basis

ⁱⁱ <https://www.diabetesatlas.org/data/en/country/93/in.html>

ⁱⁱⁱ Borgharkar SS, Das SS. Real-world evidence of glycaemic control among patients with type 2 diabetes mellitus in India: the TIGHT study. *BMJ Open Diab Res Care* 2019;7:e000654. doi:10.1136/bmjdr-2019-000654

^{iv} Pati S, Schellevis FG (2017) Prevalence and pattern of co morbidity among type2 diabetics attending urban primary healthcare centers at Bhubaneswar (India). *PLOS ONE* 12(8): e0181661. <https://doi.org/10.1371/journal.pone.0181661>